Printer friendly version Share

Library and Multimedia

Bayer Audio update: Boost for new cystic fibrosis therapy in the United States

12 March 2010 Bayer Podcast Center

The dry powder inhaler being developed by Bayer Schering Pharma for cystic fibrosis patients with chronic lung infections has been granted “orphan drug” status by the U.S. regulatory body FDA.

http://www.podcast.bayer.com/en/homepage.aspx?id=11273&application=podcast

• Allowed use: All